Palvella Therapeutics (NASDAQ:PVLA) Releases Earnings Results, Misses Estimates By $0.18 EPS

Palvella Therapeutics (NASDAQ:PVLA) released its quarterly earnings results on Tuesday. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18), FiscalAI reports.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $81.54 on Thursday. Palvella Therapeutics has a 52-week low of $11.17 and a 52-week high of $83.00. The firm has a market cap of $901.83 million, a price-to-earnings ratio of -21.51 and a beta of -0.05. The business’s fifty day moving average is $67.71 and its 200-day moving average is $44.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its stake in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at $85,000. Intech Investment Management LLC bought a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at $259,000. BNP Paribas Financial Markets acquired a new stake in shares of Palvella Therapeutics during the second quarter worth $104,000. Finally, New York State Common Retirement Fund bought a new position in Palvella Therapeutics during the second quarter worth $110,000. Institutional investors own 40.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on PVLA shares. Lifesci Capital began coverage on Palvella Therapeutics in a report on Monday, August 4th. They set an “outperform” rating and a $90.00 target price on the stock. Cantor Fitzgerald upped their price objective on Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. TD Cowen lifted their target price on Palvella Therapeutics from $65.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright lifted their price objective on shares of Palvella Therapeutics from $95.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.67.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.